Back to User profile » Professor Leslie Citrome
Papers published by Professor Leslie Citrome:
Clinical Benefit and Risk Profile of TV-46000 for Patients with Schizophrenia as Assessed by Number Needed to Treat and Number Needed to Harm
Citrome L, Franzenburg KR, Suett M, Tohami O, Sharon N, Jehassi A, Harary E, Yu D, Correll CU
Neuropsychiatric Disease and Treatment 2026, 22:534730
Published Date: 8 May 2026
The Clinically Meaningful Score Difference and Meaningful Score Regions in Positive and Negative Syndrome Scale Total Score from Post Hoc Analyses of a Phase 3 Pivotal Clinical Trial of Transdermal Asenapine in Patients with Schizophrenia
Citrome L, Czobor P, Komaroff M, Khan M, Hasebe M, Terahara T
Neuropsychiatric Disease and Treatment 2026, 22:562499
Published Date: 21 March 2026
Prescriber- and Patient-Level Characteristics Associated with Patient Adherence to Any Antipsychotics Among Patients with Schizophrenia in the United States
Voegel A, Naranjo RR Jr, Diaz L, Vanden Eynde C, Wang Y, Pilon D, Benson C, Citrome L
Patient Preference and Adherence 2026, 20:570441
Published Date: 17 February 2026
Brexpiprazole in the Management of Schizophrenia: A Consensus Report of Best Practices From Acute to Maintenance Treatment
Correll CU, Mafi CE, Fagiolini A, Seerden P, Seifritz E, Tiihonen J, Vita A, Citrome L
Neuropsychiatric Disease and Treatment 2025, 21:1857-1883
Published Date: 29 August 2025
Aripiprazole Lauroxil Every 2 Months or Paliperidone Palmitate Monthly for Acute Schizophrenia: A Post Hoc Analysis of PANSS Five-Factor Scores in the ALPINE Trial
Citrome L, Dunbar M, McGrory JA
Neuropsychiatric Disease and Treatment 2025, 21:1047-1055
Published Date: 14 May 2025
Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
Citrome L, Neugebauer NM, Meli AA, Kando J
Neuropsychiatric Disease and Treatment 2025, 21:761-773
Published Date: 5 April 2025
Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
Citrome L, Correll CU, Cutler AJ, Dunbar M, Hoberg AR, Hopkinson C, Mattingly GW, McGrory JA, Rege B, Weiden PJ, McDonnell D
Neuropsychiatric Disease and Treatment 2025, 21:575-596
Published Date: 14 March 2025
Preclinical Evidence for the Use of Brexpiprazole + Antidepressant Treatment for Major Depressive Disorder and Post-Traumatic Stress Disorder: A Systematic Review
Brubaker M, Kapadia S, Maletic V, Chambers JS, Watling CP, Citrome L
Neuropsychiatric Disease and Treatment 2025, 21:421-436
Published Date: 28 February 2025
Introducing S.C.O.P.E.™ (Schizophrenia Clinical Outcome Scenarios and Patient–Provider Engagement), an Interactive Digital Platform to Educate Healthcare Professionals on Schizophrenia Care
Correll CU, Rubio JM, Citrome L, Mychaskiw MA, Thompson S, Franzenburg KR, Suett M, Kotak S, Kane JM
Neuropsychiatric Disease and Treatment 2024, 20:1995-2010
Published Date: 19 October 2024
TV-46000, A Long-Acting Subcutaneous Antipsychotic Agent, Demonstrated Improved Patient-Centered Outcomes in Patients with Schizophrenia
Citrome L, Suett M, Franzenburg KR, Eshet R, Elgart A, Davis GL 3rd, Harary E, Tohami O, Mychaskiw MA, Kane JM
Neuropsychiatric Disease and Treatment 2024, 20:1901-1917
Published Date: 9 October 2024
Impact of Demographics and Insurance Coverage on Schizophrenia Treatment and Healthcare Resource Utilization Within an Integrated Healthcare System
Seo S, Healey BE, McLin R, Sacks NC, Benson CJ, Citrome L
Neuropsychiatric Disease and Treatment 2024, 20:1837-1848
Published Date: 26 September 2024
Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis
Citrome L, Castelli M, Hasebe M, Terahara T, Faden J, Komaroff M
Neuropsychiatric Disease and Treatment 2024, 20:755-764
Published Date: 29 March 2024
What to Expect in 2024: Important Health Economics and Outcomes Research (HEOR) Trends
Abraham I, Hiligsmann M, Lee KKC, Citrome L, Colombo GL, Gregg M
ClinicoEconomics and Outcomes Research 2023, 15:799-809
Published Date: 21 December 2023
Prioritizing Treatment Goals of People Diagnosed with Bipolar I Disorder in the US: Best–Worst Scaling Results
Bridges JFP, Goldberg JF, Fitzgerald HM, Chumki SR, Beusterien K, Will O, Citrome L
Patient Preference and Adherence 2023, 17:2545-2555
Published Date: 12 October 2023
Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD
Neuropsychiatric Disease and Treatment 2022, 18:111-123
Published Date: 26 January 2022
Perceived Burdens and Educational Needs of Caregivers of People with Schizophrenia: Results of a National Survey Study
Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD
Patient Preference and Adherence 2022, 16:159-168
Published Date: 21 January 2022